ARQT News and Press, Arcutis Biotherapeutics Inc. From 02/01/21

Roflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA Success Favorable safety and tolerability profile in this patient population New Drug Application (NDA) submission anticipated in the second half of 2021 Roflumilast ...

Arcutis Biotherapeutics (ARQT) announces that it will advance its program to develop topical roflumilast foam (ARQ-154) as a treatment for seborrheic dermatitis into Phase 3 following an End-of-Phase 2 meeting with the U.S. FDA.The Phase 3 program will consist of...

Phase 3 development to consist of single pivotal trial Previously reported data demonstrated that roflumilast foam provided statistically significant improvement and a favorable safety and tolerability profile Roflumilast foam potential “Best in Class” topical PDE4 i...

Arcutis Biotherapeutics (ARQT) has commenced pivotal Phase 3 clinical trials evaluating topical roflumilast cream ARQ-151 as a potential treatment for atopic dermatitis.“More than 19M people in the U.S. suffer from atopic dermatitis, of which at least 60% are young children, ...

Roflumilast cream potential “Best in Class” topical PDE4 inhibitor Atopic dermatitis affects approximately 19 million patients in the U.S. The Company anticipates topline data in the second half of 2022 WESTLAKE VILLAGE, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE)...

Arcutis Biotherapeutics (ARQT) announces that Matthew Moore has joined the company as chief business officer. Mr. Moore brings to the company over 20 years of strategy, transaction and operations experience in the biopharmaceutical industry. Most recently, he served a...

WESTLAKE VILLAGE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-der...

Arcutis Biotherapeutics ([[ARQT]] -4.8%) selected for addition to the NASDAQ Biotechnology Index, effective today.The addition of Arcutis Biotherapeutics to the NBI is a result of the annual reconstitution of the index announced by Nasdaq on December 11. For fu...

WESTLAKE VILLAGE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-derm...

Broad and deep portfolio of highly differentiated product candidates aligned with needs of patients and doctors Robust pipeline includes 4 development programs addressing 7 dermatological diseases, including 3 programs in Phase 2 or Phase 3 for 5 different indications Pipeline has...